Aurobindo Pharma (BOM:524804) Quick Ratio: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524804 Aurobindo Pharma Ltd BOM:524804
82 GF Score
Price ₹1,735.00
GF Value ₹1,420.96
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Aurobindo Pharma Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aurobindo Pharma's quick ratio for the quarter that ended in Jun. 2026 was .

Aurobindo Pharma has a quick ratio of . It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Aurobindo Pharma's Quick Ratio or its related term are showing as below:

BOM:524804' s Quick Ratio Range Over the Past 10 Years
Min: 0.67   Med: 1.06   Max: 1.3
Current: 1.15

During the past 13 years, Aurobindo Pharma's highest Quick Ratio was 1.30. The lowest was 0.67. And the median was 1.06.

BOM:524804's Quick Ratio is ranked worse than
57.72% of 998 companies
in the Drug Manufacturers industry
Industry Median: 1.4 vs BOM:524804: 1.15

Aurobindo Pharma  (BOM:524804) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Aurobindo Pharma Quick Ratio Related Terms


Aurobindo Pharma Quick Ratio Historical Data

* Premium members only.

The historical data trend for Aurobindo Pharma's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma Quick Ratio Chart

Aurobindo Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.30 1.13 1.15 1.13 1.15

Aurobindo Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.13 - 1.15 -

BOM:524804 vs ZTS: Quick Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma Quick Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Quick Ratio falls into.


BOM:524804
82GF Score
Aurobindo Pharma Ltd BOM:524804
Quick Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurobindo Pharma Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Aurobindo Pharma's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Quick Ratio (A: Mar. 2026 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(327087.5-120529.4)/180390.1
=1.15

Aurobindo Pharma's Quick Ratio for the quarter that ended in Jun. 2026 is calculated as

Quick Ratio (Q: Jun. 2026 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(-0)/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?

Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued. The current stock price of ₹1,735.00 is trading 22.1% above its estimated GF Value™ of ₹1,420.96. GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524804:

  • Quick Ratio:
  • GF Value™: ₹1,420.96 vs. price of ₹1,735.00 (22.1% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurobindo Pharma Business Description

Other Exchanges AUROPHARMA:India
Address Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
82GF Score

Get the complete analysis for BOM:524804

Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,735.00
Price
₹1,420.96
GF Value